Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

8.020-0.01%Vol 2491Y Perf 45.55%
Sep 23rd, 2021 08:09 DELAYED
BID7.17 ASK8.03
Open8.02 Previous Close8.02
Pre-Market8.02 After-Market-
 8.02 -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.12
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     81.66
Price Range Ratio 52W %
50.16 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha0.02 Standard Deviation0.11
Beta-0.42 

Today's Price Range

8.028.02

52W Range

4.8511.17

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-4.52%
3 Months
-18.16%
6 Months
1.91%
1 Year
45.55%
3 Years
60.40%
5 Years
14.57%
10 Years
206.35%

TickerPriceChg.Chg.%
CYCCP8.020.0000-0.01
AAPL146.770.92000.63
GOOG2 839.7220.95000.74
MSFT299.941.36000.46
XOM57.091.88003.41
WFC48.060.98002.08
JNJ165.711.78001.09
FB346.142.93000.85
GE103.905.36005.44
JPM161.415.50003.53
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume249
Shares Outstanding0
Shares Float333.94K
Trades Count4
Dollar Volume48
Avg. Volume743
Avg. Weekly Volume610
Avg. Monthly Volume777
Avg. Quarterly Volume879

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (NASDAQ: CYCCP) stock closed at 8.02 per share at the end of the most recent trading day (a 0.01% change compared to the prior day closing price) with a volume of 600.0000 shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is 45.55%, while year-to-date (YTD) performance is 14.08%. CYCCP stock has a five-year performance of 14.57%. Its 52-week range is between 4.85 and 11.17, which gives CYCCP stock a 52-week price range ratio of 50.16%

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 13.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.75%, a ROC of -49.82% and a ROE of -49.51%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a dividend yield of 7.48% with a dividend per share of $0.60 and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a Sell technical analysis rating based on Technical Indicators (ADX : 12.83, ATR14 : 0.40, CCI20 : -60.53, Chaikin Money Flow : 0.04, MACD : -0.28, Money Flow Index : 0.00, ROC : 0.00, RSI : 33.45, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 7.33, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

43%57%

Bearish Bullish

48%52%

Bearish Bullish

53%47%

News

Stocktwits